BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Gold Standard Diagnostics Announces Next Generation HE4 Ovarian Cancer Biomarker Testing Solutions


6/13/2012 10:18:06 AM

DAVIS, Calif.--(BUSINESS WIRE)--Detection of the HE4 biomarker gives medical professionals an improved tool for early detection of ovarian cancer. Gold Standard Diagnostics (GSD) provides an exclusive HE4 EIA testing solution that is certified “ThunderBolt-Ready”ensuring seamless automation on GSD’s ThunderBolt™ EIA platform. HE4 testing enables healthcare professionals to detect ovarian cancer much earlier and increase the probability of cure to 90-95%1. Ovarian cancer is not the silent killer it was once thought to be.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->